source
- Roivant reports record-breaking Phase 2 results for PH-ILD drug mosliciguat, starts Phase 3Roivant announced that its experimental drug mosliciguat met all primary and secondary endpoints in a Phase 2 study in patients with pulmonary hypertension associated with interstitial lung disease…
- Amgen reports positive lung cancer trial results for Imdelltra combined with checkpoint inhibitorAmgen announced that its T-cell engager candidate Imdelltra, when used together with a checkpoint inhibitor, showed a clinical benefit in patients with advanced lung cancer. The trial data indicat…